European cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.0% during the forecast period. The significant prevalence of cancer and increasing cancer research is driving market growth. As per the European Commission, the cancer burden is estimated to have increased to 2.7 million new cases (all kinds, excluding non-melanoma skin cancer) in 2020. This is driving the demand for monoclonal antibodies therapies for cancer therapeutics. It acts as a targeted therapy as they have a particular target on a cancerous cell. However, other monoclonal antibodies work as immunotherapy which makes the immune system respond better that support the body to more potentially find and attack cancer cells.
Get Free Sample link @ https://www.omrglobal.com/request-sample/european-cancer-monoclonal-antibodies-market
Some monoclonal antibodies that are available in the European market include Bevacizumab (Avastin), Cetuximab (Erbitux), and alemtuzumab (Campath). Increasing launches of monoclonal antibody biosimilars have also been reported in the region. For instance, in August 2020, Samsung Bioepis Co., Ltd. declared that the European Commission allowed marketing authorization for AYBINTIO (bevacizumab) to treat similar kinds of cancer as reference bevacizumab, including advanced and/or metastatic renal cell cancer (mRCC), non-small cell lung cancer (NSCLC), metastatic carcinoma of the colon or rectum (mCRC), epithelial ovarian, fallopian tube and primary peritoneal cancer, metastatic breast cancer (mBC), and cervical cancer.
A full report of European cancer monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/european-cancer-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
European Cancer Monoclonal Antibodies Market by Type
- Naked
- Conjugated
- Others (Bispecific)
European Cancer Monoclonal Antibodies Market by Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
Regional Analysis
- UK
- Germany
- France
- Spain
- Italy
- Rest of European
Company Profiles
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Co.
- Hoffmann-La Roche AG
- Genmab A/S
- GlaxoSmithKline plc
- Innate Pharma S.A.
- Mylan N.V.
- Novartis AG
- Pfizer Inc.
The Report Covers
- Comprehensive research methodology of the European cancer monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the European cancer monoclonal antibodies market.
- Insights about market determinants which are stimulating the European cancer monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/european-cancer-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
